Diethelm Tschope
Overview
Explore the profile of Diethelm Tschope including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
568
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Guckel D, Isgandarova K, Bergau L, Piran M, El Hamriti M, Imnadze G, et al.
J Clin Med
. 2021 Nov;
10(21).
PMID: 34768382
Diabetes mellitus (DM) plays a crucial role in the regulation of atrial fibrillation (AF). This study aimed to evaluate the outcome of pulmonary vein isolation (PVI) using a single-shot device...
3.
Welters A, Tittel S, Laubner K, Laimer M, Tschope D, Mader J, et al.
Diabetes Res Clin Pract
. 2021 Jul;
178:108973.
PMID: 34302914
Aims: To analyse time-trends in BMI, obesity and cardiometabolic risk in adults with type 1 diabetes (T1DM) from the Diabetes Prospective Follow-up registry DPV. Methods: Data from 62,519 individuals with...
4.
Prakasam R, Matuszewska-Iwanicka A, Fischer D, Schumann H, Tschope D, Stratmann B, et al.
Biomedicines
. 2020 Jul;
8(7).
PMID: 32630622
Optical coherence tomography (OCT) supports the detection of thickness changes in intraretinal layers at an early stage of diabetes mellitus. However, the analysis of OCT data in cross-sectional studies is...
5.
Schindler C, Birkenfeld A, Hanefeld M, Schatz U, Kohler C, Gruneberg M, et al.
Diabetes Ther
. 2018 Dec;
10(1):329-331.
PMID: 30523582
In the original publication, the text in Table 2 stated 'Hypersensitivity to the active substance, to Ferinject, or to any of its excipients'.
6.
Dandona P, Mathieu C, Phillip M, Hansen L, Tschope D, Thoren F, et al.
Diabetes Care
. 2018 Oct;
41(12):2552-2559.
PMID: 30352894
Objective: This study evaluated the long-term safety and efficacy of dapagliflozin as an adjunct to adjustable insulin in patients with type 1 diabetes and inadequate glycemic control. Research Design And...
7.
Schmieder R, Tschope D, Koch C, Ouarrak T, Gitt A
Cardiovasc Diabetol
. 2018 Jan;
17(1):18.
PMID: 29357854
Aim: Patients with type-2 diabetes mellitus (T2DM) are at high risk of cardiovascular events, accentuated in the presence of hypertension. At present, it is unclear to what extent the guidelines...
8.
Schindler C, Birkenfeld A, Hanefeld M, Schatz U, Kohler C, Gruneberg M, et al.
Diabetes Ther
. 2017 Nov;
9(1):37-47.
PMID: 29134606
Introduction: HbA1c is the gold standard for glycemic control in pre-diabetes and diabetes. However, its validity has been questioned, especially in the presence of imbalanced iron homeostasis. The CLEVER trial...
9.
Dandona P, Mathieu C, Phillip M, Hansen L, Griffen S, Tschope D, et al.
Lancet Diabetes Endocrinol
. 2017 Sep;
5(11):864-876.
PMID: 28919061
Background: Dapagliflozin is a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of dapagliflozin as an add-on to adjustable...
10.
Tschope D
J Diabetes Complications
. 2017 May;
31(7):1075-1076.
PMID: 28479154
No abstract available.